Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
In this week’s Pathways Picks: AdvaMed tries to set AI policy directions; leaked Trump budget documents suggest limited damage to FDA device program; Makary suggests steps to limit company involvement in advisory panels; China formalizes Green Channel and Priority Approval procedures; UK adopts robotic surgery, and more.
In this month's news, a flurry of 510(k) clearances (and one De Novo) and major M&A plays by Viscogliosi Brothers, Zydus Lifesciences, and more.
FDA authorized its first De Novo in the Trump era. Excerpted from Pathways’ Picks March 26: MDR Reform Input Streams In, Makary Confirmed at FDA, and More.